Empagliflozin users had 741 events compared to 712 in the DPP4i group, corresponding to a non-significant HR of 1.04. For DR progression, empagliflozin users experienced fewer events (158) than ...
Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, did not reduce the risk for incident nonproliferative diabetic retinopathy compared with dipeptidyl peptidase 4 (DPP-4 ...
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Use of empagliflozin (Jardiance) was not linked to a lower risk of incident nonproliferative diabetic retinopathy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback